Eli Lilly and Company LLY
At closeNov 12, 2026, 8:19 AM EST
Pre-market · Nov 12, 8:19 AM ET
- YTD
- +33.74%
- 1 year
- +41.22%
- Market cap
- 1.28T
- Revenue (ttm)
- 86.46B
- Profit margin
- 31.90%
- EPS (ttm)
- 30.81
- Shares out
- 890.75M
- P/E ratio
- 46.65
- Forward P/E
- 28.45
- Dividend
- 6.92 (0.49%)
- Ex-dividend date
- Nov 12, 2026
- YTD return
- +33.74%
- 1-year return
- +41.22%
- Volume
- 1.87M
- Avg volume
- 2.57M
- Open
- 1,418.08
- Previous close
- 1,432.29
- Day's range
- 1,414.77 – 1,440.35
- 52-week range
- 850.51 – 1,453.00
- Beta
- 0.39
- Analysts
- Buy
- Price target
- 1,453.40 (+1.1%)
- Earnings date
- Feb 3, 2027
5D +12.93 (+0.91%)
Key statistics
- Enterprise value
- 1.32T
- PEG ratio
- 1.32
- Price / sales
- 14.81
- Price / book
- 31.82
- Dividend yield
- 0.48%
- Payout ratio
- 21.71%
- Revenue growth
- 38.60%
- Free cash flow
- 9.34B
- Total cash
- 4.89B
- Total debt
- 49.50B
- Return on equity
- 86.02%
- Short % of float
- 0.81%
- 50-day average
- 1,224.51
- 200-day average
- 1,103.22
Analyst view
Consensus: buy
- Target (low)
- 940.00
- Target (mean)
- 1,453.40
- Target (high)
- 1,690.00
- Strong buy6
- Buy20
- Hold3
- Sell1
- Strong sell1
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 11.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 11.19 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 5.71 | 7.48 | +1.77 | +31.00% |
| Aug 5, 2026 | Jun 30, 2026 | 6.40 | 8.38 | +1.98 | +30.94% |
| Apr 30, 2026 | Mar 31, 2026 | 6.97 | 8.55 | +1.58 | +22.67% |
| Feb 4, 2026 | Dec 31, 2025 | 6.91 | 7.54 | +0.63 | +9.12% |
| Oct 30, 2025 | Sep 30, 2025 | 5.69 | 7.02 | +1.33 | +23.37% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Jefferies | main | Buy | Buy |
| Nov 2, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Oct 30, 2026 | UBS | main | Buy | Buy |
| Oct 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 30, 2026 | Citigroup | main | Buy | Buy |
| Oct 30, 2026 | Scotiabank | main | Sector Outperform | Sector Outperform |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- lilly.com
News
China approves Eli Lilly's weight loss pill orforglipron 
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner? 
Pfizer And Blackstone Life Sciences Enter Co-Funding Agreement Under Which Blackstone Will Pay Up To $1.5B Of Development Costs For Study Of Monthly GLP-1 Receptor Agonist Peptide Berobenatide Through 2028 
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027? 
Eli Lilly Says Taltz/Zepbound Combo Shows Long-Term Efficacy in Psoriatic Arthritis Trial 
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat 
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat 
Eli Lilly Reports 52-Week Results Showing Improved Efficacy From TOGETHER-Psa Phase 3b Open-Label Clinical Trial Evaluating Taltz-Zepbound Combination In Psoriatic Arthritis 
Lilly Highlights Phase 3b Data On Taltz, Zepbound 
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
Your note
Sign in to keep a note on LLY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALVAREZ RALPH | Director | Stock Award(Grant) | Oct 18, 2026 | 56,606 |
| FYRWALD J. ERIK | Director | Stock Award(Grant) | Oct 18, 2026 | 75,544 |
| HAKIM ANAT | General Counsel | Sale | Nov 1, 2026 | 0 |
| HERNANDEZ EDGARDO | Officer | Conversion of Exercise of derivative security | Oct 29, 2026 | 48,364 |
| JONSSON PATRIK | Officer | Sale | Aug 16, 2026 | 54,779 |
| LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | May 5, 2026 | 91,881,200 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lilly Endowment, Inc | 9.57% | 90,066,978 | 129.49B | Sep 29, 2026 |
| Blackrock Inc. | 7.18% | 67,540,400 | 97.11B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 5.69% | 53,528,868 | 76.96B | Jun 29, 2026 |
| PNC Financial Services Group, Inc. | 5.45% | 51,295,197 | 73.75B | Sep 29, 2026 |
| State Street Corporation | 3.85% | 36,215,754 | 52.07B | Jun 29, 2026 |
| FMR, LLC | 3.18% | 29,959,147 | 43.07B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.86% | 26,907,512 | 38.69B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.18% | 20,499,297 | 29.47B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.13% | 10,662,009 | 15.33B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.11% | 10,398,764 | 14.95B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.05% | 9,899,468 | 14.23B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Growth Index Fund | 0.94% | 8,873,900 | 12.76B | Jun 29, 2026 |